Peter O'Donnell, ACT's Brussels Correspondent
Advertisement
Peter O'Donnell is a freelance journalist who specializes in European health affairs and is based in Brussels, Belgium.
Articles by Peter O'Donnell, ACT's Brussels Correspondent
Findings show big pharma increasingly turning to other companies for molecules to stock its pipeline.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
3
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
4
Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
